Who We Are
Since GI Dynamics’ founding in 2003, our mission has been to alleviate the symptoms of type 2 diabetes and obesity for patients fighting these global epidemics worldwide.
Our revolutionary EndoBarrier® is a testament to the GI Dynamics mission. The first endoscopically inserted treatment for the management of type 2 diabetes and obesity. Both minimally invasive and completely reversible, EndoBarrier bridges the gap between pharmaceuticals and surgery by providing a safer and more effective way to control glucose and lose weight for individuals who are underserved by drugs and injections, but for whom surgery is not an option.
GI Dynamics is headquartered in Boston, Massachusetts, with offices in Europe and Australia. Our team of business experts and industry veterans have a successful track record of pioneering and commercializing breakthrough healthcare technologies. While not yet available in the US, EndoBarrier is approved and commercially available, dramatically improving lives around the globe.